DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/94d0a4/mexico_pharmaceuti) has announced the addition of the "Mexico Pharmaceuticals and Healthcare Report Q1 2012" report to their offering.
Business Monitor International's Mexico Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Mexico's pharmaceuticals and healthcare industry.
BMI View:
Despite the generally positive outlook for much of Latin America in 2012, BMI maintains the view that mounting fiscal pressures and a faltering business environment will damage Mexico's attractiveness to multinational drugmakers. Beyond ongoing policy concerns, BMI believes consumer acceptance of black-market low-cost medicines will continue to define the country's pharmaceutical marketplace, regardless of the favourable wording used in new intellectual property (IP) and patent standards.
Key Trends And Developments:
In October 2011, BMI reported on continuing disputes over Mexico's largest public scheme, the Institute for Social Security and Services for State Workers (ISSSTE).
In September 2011, Mexico's Ministry of Health announced it will launch a national drug voucher programme to help public health schemes and dispensaries that have faced an increasing number of medicine shortages since 2010.
Speaking at the National Convention of Health Officers (Convecion Nacional de Responsables Sanitarios de la Industria Quimico Farmaceutica) in August 2011, Health Secretary Crdova Villalobos announced his government's plan to ease Secretaria de Salud (SSA) registration requirements for low-risk products.
Also in August 2011, Mexico's Federal Commission for Protection Against Health Risks (COFEPRIS, Comisin Fedral para la Proteccin contra Riesgos Sanitarios) called on pharmacies, distributors and drug manufacturers to help curb the country's black market trade of pharmaceuticals.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Market Summary
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Mexico Demographic Data
- Methodology
Companies Mentioned:
- Bayer
- Boehringer Ingelheim
- Bristol Myers Squibb (BMS)
- Eli Lilly
- Genomma Labs
- GlaxoSmithKline (GSK)
- Liomont
- Merck KGaA
- Novartis
- Sanofi-Aventis
- Solara/Strides Arcolab
- Pfizer
- Roche Syntex
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/94d0a4/mexico_pharmaceuti